What are the effects and recommended use of Jardiance (empagliflozin) in patients with heart failure with reduced ejection fraction (HFrEF)?

Jardiance (Empagliflozin) in HFrEF: A Cornerstone Therapy

Jardiance (empagliflozin) 10 mg once daily should be initiated in all patients with HFrEF (LVEF ≤40%), regardless of diabetes status, to reduce cardiovascular death and heart failure hospitalizations. This recommendation is based on the EMPEROR-Reduced trial and is now FDA-approved for this indication 1.

Core Clinical Benefits

The evidence from EMPEROR-Reduced demonstrates that empagliflozin provides:

• 25% reduction in the composite endpoint of cardiovascular death or heart failure hospitalization (HR 0.75,95% CI 0.65-0.86) 2, 3
• 31% reduction in heart failure hospitalizations specifically (HR 0.69,95% CI 0.59-0.81) 1
• 30% reduction in first and recurrent hospitalizations for heart failure (HR 0.70,95% CI 0.58-0.85) 1
• Benefits emerge within 12 days of treatment initiation and are sustained long-term 4

The cardiovascular mortality benefit was not statistically significant as a standalone endpoint (HR 0.92,95% CI 0.75-1.12), but the reduction in morbidity and quality of life improvements are clinically meaningful 1.

Who Should Receive Jardiance

Initiate empagliflozin in:

• All symptomatic HFrEF patients (NYHA Class II-IV) with LVEF ≤40%
• Patients with or without type 2 diabetes (benefits are consistent across both groups) 2, 5, 6
• Patients already on maximally tolerated guideline-directed medical therapy (GDMT) including ACE inhibitors/ARBs/ARNI, beta-blockers, and mineralocorticoid receptor antagonists 2

Dosing:

• Start: 10 mg once daily
• Target: 10 mg once daily (no titration needed)
• Can be initiated early in disease course; do not wait for complete GDMT optimization 2

Renal Considerations

eGFR thresholds matter:

• Safe and effective down to eGFR ≥20 mL/min/1.73 m² based on EMPEROR-Reduced exclusion criteria 2
• Very limited data below eGFR 30 mL/min/1.73 m² (DAPA-HF excluded these patients) 2
• Not recommended for glycemic control when eGFR <30 mL/min/1.73 m², but still indicated for heart failure benefits 1
• Continue therapy even if eGFR declines during treatment, as empagliflozin slows eGFR decline over time 1

Integration with Other HF Therapies

Empagliflozin works additively with other GDMT:

• No treatment interactions with baseline ACE inhibitors, ARBs, ARNI (used in 19% of EMPEROR-Reduced patients), beta-blockers, or MRAs 2
• Benefits maintained regardless of whether patients are on sacubitril-valsartan 5
• Can be started alongside or after other GDMT components—do not delay initiation 2

Functional and Quality of Life Benefits

Beyond mortality and hospitalization reduction:

• 20-40% greater likelihood of NYHA functional class improvement 4
• 20-40% lower likelihood of NYHA functional class worsening 4
• Improvements apparent at 28 days and maintained long-term 4
• Reduces need for diuretic intensification by 33% (HR 0.67,95% CI 0.56-0.78) 4

Cardiac Remodeling Effects

Empagliflozin promotes reverse cardiac remodeling:

• Reduces LV end-diastolic volume by 17 mL and LV end-systolic volume by 16 mL 7
• Increases LVEF by approximately 3% (WMD 2.96%, 95% CI 0.84-5.09) 7
• Reduces left atrial volume index by 2.16 mL/m² 7
• Effects on RV function are most pronounced in patients with baseline RV dysfunction 8, 9

Safety Profile

Empagliflozin is remarkably safe in HFrEF:

• No excess hypovolemia, hypoglycemia, or renal adverse events compared to placebo 2
• No increased risk of ketoacidosis in non-diabetic HFrEF patients 5
• No increased amputations (a concern with some other SGLT2 inhibitors in diabetes trials) 5

Common pitfall to avoid: Do not withhold empagliflozin due to concerns about volume depletion—the EMPEROR-Reduced trial showed benefits were not mediated primarily by diuresis, and effects were consistent regardless of baseline volume status 10.

Practical Implementation

Start empagliflozin:

1. At any point after HFrEF diagnosis—early initiation is encouraged 2
2. Without waiting for complete uptitration of other GDMT
3. In both inpatient (before discharge) and outpatient settings
4. Regardless of current diuretic dose or volume status

Monitor:

• Renal function at baseline and periodically (but do not discontinue for mild eGFR decline)
• Volume status (though diuretic reduction is often possible)
• Functional status and symptoms (expect improvement within 4 weeks)

Guideline Consensus

The 2021 CCS/CHFS guidelines provide a Strong Recommendation with High-Quality Evidence for SGLT2 inhibitors (including empagliflozin) in HFrEF 2. The 2022 AHA/ACC/HFSA guidelines similarly endorse SGLT2 inhibitors as foundational therapy 11, 12. This represents a paradigm shift: empagliflozin is now considered a cornerstone of HFrEF therapy, not an add-on treatment.

Bottom line: Empagliflozin 10 mg daily should be standard therapy for virtually all HFrEF patients with LVEF ≤40% and eGFR ≥20 mL/min/1.73 m², initiated early and maintained long-term alongside other GDMT components 2, 1.